Share-based Payment Arrangement, Expense of Passage BIO, Inc. from 31 Mar 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Passage BIO, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2019 to 30 Sep 2025.
  • Passage BIO, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $611,000, a 56% decline year-over-year.
  • Passage BIO, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $3,639,000, a 41% decline year-over-year.
  • Passage BIO, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $5,820,000, a 47% decline from 2023.
  • Passage BIO, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $10,921,000, a 42% decline from 2022.
  • Passage BIO, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $18,954,000, a 42% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Passage BIO, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $3,639,000 $611,000 -$789,000 -56% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $4,428,000 $923,000 -$655,000 -42% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $5,083,000 $858,000 -$737,000 -46% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $5,820,000 $1,247,000 -$323,000 -21% 01 Oct 2024 31 Dec 2024 10-K 04 Mar 2025 2024 FY
Q3 2024 $6,143,000 $1,400,000 -$1,424,000 -50% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $7,567,000 $1,578,000 -$2,165,000 -58% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $9,732,000 $1,595,000 -$1,189,000 -43% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $10,921,000 $1,570,000 -$1,907,000 -55% 01 Oct 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
Q3 2023 $12,828,000 $2,824,000 -$38,000 -1.3% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $12,866,000 $3,743,000 -$2,535,000 -40% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $15,401,000 $2,784,000 -$3,553,000 -56% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $18,954,000 $3,477,000 -$4,098,000 -54% 01 Oct 2022 31 Dec 2022 10-K 04 Mar 2024 2023 FY
Q3 2022 $23,052,000 $2,862,000 -$3,953,000 -58% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $27,005,000 $6,278,000 -$2,283,000 -27% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $29,288,000 $6,337,000 -$3,403,000 -35% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $32,691,000 $7,575,000 +$3,251,000 +75% 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2023 2022 FY
Q3 2021 $29,440,000 $6,815,000 +$2,782,000 +69% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $26,658,000 $8,561,000 +$4,706,000 +122% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $21,952,000 $9,740,000 +$7,372,000 +311% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 $14,580,000 $4,324,000 +$3,288,000 +317% 01 Oct 2020 31 Dec 2020 10-K 03 Mar 2022 2021 FY
Q3 2020 $11,292,000 $4,033,000 +$3,938,000 +4145% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $7,354,000 $3,855,000 +$3,763,000 +4090% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $3,591,000 $2,368,000 +$2,137,000 +925% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q4 2019 $1,454,000 $1,036,000 01 Oct 2019 31 Dec 2019 10-K 03 Mar 2021 2020 FY
Q3 2019 $95,000 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2020 Q3
Q2 2019 $92,000 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020 2020 Q2
Q1 2019 $231,000 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1

Passage BIO, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $5,820,000 -$5,101,000 -47% 01 Jan 2024 31 Dec 2024 10-K 04 Mar 2025 2024 FY
2023 $10,921,000 -$8,033,000 -42% 01 Jan 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
2022 $18,954,000 -$13,737,000 -42% 01 Jan 2022 31 Dec 2022 10-K 04 Mar 2024 2023 FY
2021 $32,691,000 +$18,111,000 +124% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2023 2022 FY
2020 $14,580,000 +$13,126,000 +903% 01 Jan 2020 31 Dec 2020 10-K 03 Mar 2022 2021 FY
2019 $1,454,000 01 Jan 2019 31 Dec 2019 10-K 03 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.